Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06747143 in Acute Myeloid Leukemia
NCT02954653Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06747143 in acute myeloid leukemia (AML) (4 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events at 1 year and 4 more. Started Nov 2016; status: terminated.
02
Drugs
PF-06747143
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02954653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954653.